Lanthionine is a non‑proteinogenic thioether‑containing amino acid characterized by a covalent bond between the β‑carbons of two alanine residues, resulting in a 2,5‑dimethyl‑thiazolidine ring structure. It is not incorporated into proteins by the ribosomal machinery but occurs naturally in certain bacterial peptide antibiotics and ribosomally synthesized and post‑translationally modified peptides (RiPPs).
Chemical structure and properties
- Molecular formula: C₆H₁₂N₂O₂S
- IUPAC name: 2,5‑dimethyl‑1,4‑thiazane‑4‑carboxylic acid
- The thioether linkage confers resistance to proteolytic degradation and contributes to the stability of peptide frameworks in which lanthionine is embedded.
Biological occurrence
| Natural source | Representative compounds | Role of lanthionine |
|---|---|---|
| Gram‑positive bacteria (e.g., Streptomyces, Bacillus) | Nisin, subtilin, gallidermin | Forms lanthionine (β‑thioether) bridges that cyclize the peptide, creating the characteristic lanthipeptide topology |
| Archaeal and bacterial ribosomally‑synthesized peptides | Lantibiotics, thiopeptides | Provides structural rigidity and mediates interaction with bacterial membranes |
Biosynthesis
The biosynthetic pathway of lanthionine bridges involves two key enzymatic steps:
- Dehydration – Serine or threonine residues in a precursor peptide are enzymatically dehydrated to form dehydroalanine (Dha) or dehydrobutyrine (Dhb).
- Michael addition – A cysteine thiol attacks the electrophilic α,β‑unsaturated carbonyl of Dha/Dhb, generating a thioether bond and yielding a (methyl)lanthionine residue.
These reactions are catalyzed by dedicated lanthipeptide synthetases (e.g., LanB, LanC, or multifunctional LanM enzymes) that are encoded in operons adjacent to the structural gene for the precursor peptide.
Pharmacological relevance
Lanthionine‑containing peptides, especially the class of lantibiotics, display potent antimicrobial activity against Gram‑positive pathogens, including antibiotic‑resistant strains such as Methicillin‑resistant Staphylococcus aureus (MRSA). The thioether bridges impart resistance to proteases and enhance membrane‑targeting properties, making these molecules valuable leads for novel antibiotic development.
Synthetic applications
Chemical synthesis of lanthionine and its derivatives is employed in the preparation of analogues of natural lantibiotics, enabling structure‑activity relationship (SAR) studies. Solid‑phase peptide synthesis (SPPS) strategies often incorporate protected lanthionine residues or perform post‑synthetic cyclization to install the thioether linkage.
References (selected)
- Cotter, P. D., Ross, P., & Hill, C. (2005). Bacteriocins—a viable alternative to antibiotics? Nature Reviews Microbiology, 3(3), 222‑230.
- Willey, J. M., & van der Donk, W. A. (2019). Biosynthesis and mode of action of lantibiotics and other ribosomally synthesized and post‑translationally modified peptide antibiotics. Annual Review of Biochemistry, 88, 277‑306.
- Gu, W., et al. (2022). Enzymatic construction of lanthionine bridges in ribosomally synthesized peptides. Chemical Reviews, 122(1), 321‑368.
Lanthionine remains a distinct chemical entity within the broader family of thioether‑containing amino acid residues, notable for its structural role in the activity and stability of a variety of biologically active peptide natural products.
